ImmunityBio, Inc. (IBRX)
Healthcare
- Fundamental
- 2
- Sentiment
- 4
- Technical
- 2
Do Nothing: 11 core indicators failed to load, so the technical read is unreliable; fundamentalScore is also 2, below the required floor of 3.
Company overview
ImmunityBio, Inc. is a clinical-stage biotechnology company based in San Diego, focused on developing therapies and vaccines for cancers and infectious diseases. The company's platforms include immunotherapy and cell therapy technologies, with several candidates in Phase II or III trials targeting various tumors and pathogens. ImmunityBio collaborates with organizations like the National Cancer Institute and holds multiple licensing agreements.
Fundamental
weakImmunityBio's fundamentals are characterized by significant cash burn, negative equity, and complex financing obligations.
Commercial traction is improving rapidly, but the company is still far from self-funding: sales are ramping, yet losses, negative free cash flow, negative equity, and sizable financing liabilities keep the risk profile elevated. With valuation expensive on sales and intrinsic-value models screening unattractive, it fits better as a high-risk execution/catalyst story than a stable fundamentals-led investment today.
Sentiment
goodRecent regulatory and revenue announcements have driven positive media sentiment and retail interest.
Media tone has been strongly positive over the last ~14 days on ANKTIVA’s UAE marketing authorization (announced 2026-07-29) and a record Q2 net-product-revenue update (announced 2026-08-04). The 30–90d sentiment delta is indeterminate (baseline pull unusable this run), but the near-term setup remains supported by these announced catalysts and no regulator-confirmed investigation surfaced (only background plaintiff-law-firm class-action solicitations).
Technical
weakTechnical indicators failed to load, making the technical read unreliable.
Technical toolchain degraded: all TECHNICALMCP quote/chart/indicator calls failed to load, so the indicator suite is unavailable and the technical read is unreliable.
You’re looking at 2026-08-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.